Squarepoint’s Alzamend Neuro ALZN Stock Holding History
Bought
Maintained
Sold
Other funds holding ALZN
RA
KCIA
Squarepoint's ALZN Position: Q2 2022 in Review
Squarepoint sold out of Alzamend Neuro (ALZN) in Q2 2022, closing a stake of 15 shares — an estimated $24K sold.
Squarepoint first reported a position in ALZN in Q1 2022 and held it in 1 quarter. The position peaked at $24K in Q1 2022. 20 funds tracked by Wall St. Rank hold ALZN as of Q2 2022.
- Squarepoint reported no remaining Alzamend Neuro position as of Q2 2022 after selling out during the quarter.
- Squarepoint sold 15 Alzamend Neuro shares in Q2 2022, an estimated $24K.
- Squarepoint first reported a position in Alzamend Neuro in Q1 2022 and held it in 1 quarter.
- Squarepoint's Alzamend Neuro position peaked at $24K in Q1 2022.
- 20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2022.
Based on Squarepoint's 13F filing for Q2 2022, filed 15 Aug 2022.